ISSN:
1524-475X
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
The understanding of bioengineered tissue has evolved over the past 5 years. Now considered “cell therapy,” bioengineered tissue can provide a nonhealing wound with the appropriate complement of cytokines, growth factors, and healthy cells to promote the patient’s healing process. As clinicians have gained experience with Apligraf*, the process of wound bed preparation has proven to be a critical step in order to achieve optimal outcomes with the tissue construct. Recently, the investigators have evaluated a novel device, MIST† ultrasound , recently FDA cleared for the cleansing and debriding of wounds. A subgroup from a total of 23 patients in a research trial using MIST therapy for nonhealing wounds received an Apligraf as part of their treatment regimen. The'bioengineered tissue remained intact for a full 4 weeks postapplication and the appearance of the graft was quite different than our prior experience with the product. On removal of the wound/graft eschar, patients had achieved complete epithelialization. This report describes the patients who underwent this combination of technologies along with wound photographs, measurements and patient histories. As we learn more about the biochemistry of healing we are able to “look” at how we combine and use advanced wound care technologies.Acknowledgments: This study was supported from a grant from Celleration Inc.Product notation: * Apligraf® is a registered trademark of Novartis, Inc., East Hanover, NJ © 2004 Organogenesis, Inc., Canton, MA † MIST™ ultrasound is a registered trademark of Celleration Inc., Eden Prairie, MN.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1111/j.1067-1927.2005.130216ag.x
Permalink